Chuen Kwok, MD
Urology · Deridder, LANPI 1851369920
Payments from drug & device makers
Across 18 payments — averaging $43.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$564
- Sumitomo Pharma America, Inc.$79
- Travere Therapeutics, Inc.$44
- Teleflex LLC$30
- Neotract Inc.$29
- E.r. Squibb & Sons, L.L.C.$16
- plus $16 from 1 others
What the payments were for
- Food & beverage$30039%
- Education$47861%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 7 | $564 |
| Sumitomo Pharma America, Inc. | 4 | $79 |
| Travere Therapeutics, Inc. | 2 | $44 |
| Teleflex LLC | 1 | $30 |
| Neotract Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Convatec Inc. | 1 | $16 |
How this compares
$778 in reported general payments places this provider in the 20th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 130 | $80,362 |
| MyrbetriqMirabegron | 57 | $38,587 |
| Tamsulosin Hcl | 667 | $8,646 |
| ElmironPentosan Polysulfate Sodium | 13 | $8,632 |
| Finasteride | 442 | $6,167 |
| Potassium Citrate ErPotassium Citrate | 72 | $4,807 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 135 | $3,945 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 46 | $2,841 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 155 | $1,836 |
| Dutasteride | 73 | $1,755 |
| Testosterone | 22 | $1,507 |
| Oxybutynin Chloride ErOxybutynin Chloride | 42 | $820 |
| Tolterodine Tartrate ErTolterodine Tartrate | 13 | $392 |
| Trospium Chloride | 27 | $377 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 23 | $339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $79 | $80,362130 claims |
| Astellas Pharma US IncMyrbetriq | $564 | $38,58757 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 199 urology providers in Louisiana.
Other urology in Deridder
- Ralph HendersonShreveport$4M
- Kevin ClineShreveport$1.3M
- Nathan FischmanNew Orleans$1.3M
- Ashley BakerShreveport$705K
- Colin GoudelockeNew Orleans$615K
- Stephen BardotNew Orleans$572K
- Gerard HenryBossier City$489K
- Jared MossShreveport$365K
- Richard VanlangendonckNew Orleans$289K
- James NobleShreveport$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.